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Headaches are universal experiences and among the most common disorders. While headache may be physiological in the acute
setting, it can become a pathological and persistent condition.The mechanisms underlying the transition from episodic to chronic
pain have been the subject of intense study. Using physiological and imaging methods, researchers have identified a number of
different forms of neural plasticity associated with migraine and other headaches, including peripheral and central sensitization,
and alterations in the endogenous mechanisms of pain modulation. While these changes have been proposed to contribute to
headache and pain chronification, some findings are likely the results of repetitive noxious stimulation, such as atrophy of brain
areas involved in pain perception and modulation. In this review, we provide a narrative overview of recent advances on the
neuroimaging, electrophysiological and genetic aspects of neural plasticity associated with the most common forms of chronic
headaches, including migraine, cluster headache, tension-type headache, and medication overuse headache.
1. Introduction
In its 2010Global Burden ofDisease Survey, theWorldHealth
Organization reported tension-type headache (TTH) and
migraine as the second (20.1%) and third (14.7%)most preva-
lent disorders in the world, exceeded only by dental caries [1].
An earlier meta-analysis of 107 studies reported the one-year
prevalence of headaches among adults to be a staggering 46%,
with TTH (42%), migraine (11%), and chronic daily headache
(3%) standing out as the most common types [2]. With such
statistics, headache has taken its place among the disorders
plaguing the global population.
While such a commonplace condition may be easily
dismissed, the impact of headache is not to be taken lightly.
Using “years living with disability” as a measure of disease
impact, the WHO rated migraine as the 7th most disabling
of all 289 diseases surveyed (excluding the nonspecific
“other musculoskeletal disorders”) [1]. In conditions such as
migraine and other headaches, the chronicity of the disorder
itself may have profound negative impacts. Compared to
episodic headache, chronic headache has been associated
withmore disability, reduced quality of life, and greater direct
and indirect economic losses [3, 4]. While the definitions
of chronic headaches will vary with their subtypes, as will
their individual impacts, the great personal toll associated
with chronic headache is well illustrated by chronic daily
headache, whose sufferers experience headache for ≥15 days
per month, for >3 months [5].
Unfortunately, the mechanisms responsible for the devel-
opment of chronic headaches remain unknown. Barring
rare exceptions such as “new daily persistent headache,”
most patients with chronic headaches initially experience
only episodic attacks [6]. While it is still unclear why some
individuals go on to develop chronicity, epidemiological
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studies report a number of risk factors, including obesity,
history of frequent headache (>one per week), overuse of
analgesics (>10 or 15 days/month), and caffeine consumption,
among others [7]. As the search for a mechanism continues,
numerous hypotheses have been put forth regarding the role
of neural plasticity in headache chronification.
Thanks to recent advances in electrophysiology and
neuroimaging, now we are able to test these hypotheses
directly on the human brain. In this review, we first provide
a narrative overview of the most common forms of chronic
headaches and then discuss the neural plasticity underlying
specific headache disorders by comparing available electro-
physiological and neuroimaging studies in their episodic and
chronic forms, according to the tools used and the hypotheses
proposed. Emphasis will be laid on migraine as it is the most
well studied type of these headaches.
2. Common Forms of Chronic Headache
2.1. Chronic Migraine. Although it is not the most common
of the headache disorders we will discuss, migraine headache
is by far the most disabling and most researched condition
[1]. According to the definitions put forth by the International
Classification of Headache Disorder, migraine consists of
recurrent unilateral throbbing headache attacks of moderate
to severe intensity that are aggravated by physical activity
[8]. Associated symptoms include nausea, vomiting, and
hypersensitivity to light and/or sound [8]. Patients with
migraine could have aura, a transient visual, sensory, or other
central nervous system symptoms before or concurrent with
headache [8]. While most patients experience infrequent
episodic attacks (episodic migraine, EM), some patients may
have chronic migraine (CM) defined as any headaches for
≥15 days per month and headache with the above migraine
characteristics for ≥8 days per month, for >3 months [8].
Although the mechanisms underlying migraine headache
remain debated, there is likely an interaction between genetic
predisposition and environmental factors at work [9]. These
two components together may be responsible for increased
overall migraine susceptibility and for the development of
cortical spreading depression—the electrical phenomenon
underlying migraine aura [9].
2.2. Chronic Cluster Headache. CH is a primary headache
disorder characterized by severe, strictly unilateral pain,
lasting from 15 to 180 minutes [8]. Accompanying these
attacks, patients usually experience ipsilateral cranial auto-
nomic symptoms (tearing, conjunctive ejection, nasal con-
gestion, rhinorrhea, forehead sweating,miosis, ptosis, and ear
fullness) and a feeling of agitation. Unlike most other forms
of headache, CH tends to occur in “bouts,” with patients
experiencing regular and frequent attacks for a period of time.
However, as many as 21% of patients develop chronic CH,
they suffer from at least one CH per month for at least one
year. Interestingly, the prevalence of chronic CH appears to
be low in Asians [10].
2.3. Chronic Tension-Type Headache. TTH is the most
common type of headache [11]. Unlike migraine, TTH is
a “featureless” headache—usually mild, bilateral, nonpul-
satile (pressing), and not aggravated by daily activities.
Common migraine-associated symptoms, including nausea
and vomiting, are usually absent in TTH, although mild
photo- or phonophobia may be present [11]. As a result
of its comparatively mild severity, TTH has remained out
of the medical and research spotlight. Nonetheless, it has
been found to significantly increase healthcare utilization
and work absence rates and consequently remains costly to
society [12].Moreover, likemigraine, TTHcan evolve from its
episodic form to a chronic condition (chronic TTH, defined
as ≥15 headache days/month). Chronic TTH is extremely
disabling and is regarded as one of the most neglected and
difficult to treat forms of headache [13].
2.4. Medication Overuse Headache. MOH results from regu-
lar overuse of abortive medication, exceeding 10 or 15 days
per month (depending on the analgesic), for more than 3
months [8]. While MOH is defined as a distinct secondary
headache syndrome, it is also commonly associated with
primary headaches. While the prevalence of MOH in the
general population is only 1-2% according to epidemiological
studies, it may in fact be the most common type of headache
to present in specialty clinics [55]. MOH is a recognized risk
factor for headache evolution, especially when resulting from
the use of barbiturates and triptans [6, 7].
3. Electrophysiological Evidence of Neural
Plasticity in Chronic Headaches
3.1. Central Sensitization. Sensitization of the trigeminal
pain network (i.e., even beyond the first-order neuron) has
been proposed to underlie migraine pathophysiology. As
shown by the animal studies conducted by Burstein and col-
leagues, applying brief chemical stimulation with inflamma-
tory agents to the dura in rats led to peripheral sensitization
of the first-order neurons in the dorsal root ganglia of C2/C3
and trigeminal ganglion and central sensitization of the
second order neurons in the trigeminal nucleus caudalis (also
known as trigeminocervical complex). As a result, the rats
treated with inflammatory agents had increased excitability
in response to brush or nonnoxious heat stimulation [56–
58]. This same sensitization, in a subset of migraine patients
who experience extracranial pain, may extend to third order
neurons in the thalamus as well [59]. In support of this,
further work from the same group provides evidence of
central sensitization in the thalamus, both in the rat model
described above and in findings of exaggerated thalamic
functional MRI (fMRI) activation in human migraineurs
experiencing cutaneous allodynia during ictal periods [60].
Electrophysiological studies of trigeminal processing also
characterize neural plasticity in association with CH [61],
although the findings are diverse and sometimes conflicting.
While the classic blink reflex has repeatedly shownno signs of
sensitization [62, 63], a number of other studies suggest CH
is accompanied by a general sensitization of pain processing
[14]. Researchers have found evidence of faster rates of R2
blink reflex recovery after supraorbital paired pulse elec-
tric stimulation, perhaps indicating reduced central opioid
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activity [64]. Studies have also reported increased excitability
of trigeminal processing on the affected side of the head
compared to the unaffected side [65–68]. Moreover, studies
have consistently shown reduced thresholds of pressure pain,
electric pain, nociceptive corneal reflex, and RIII reflex on the
symptomatic side relative to the asymptomatic side, in both
episodic and chronic CH [62, 69–71].
In TTH, evidence is mounting in support of a neural
plasticity characterized by central sensitization. An intrigu-
ing study in patients with chronic TTH showed increased
suprathreshold pain sensitivity both in skin and in muscle,
and in both cephalic and extracephalic regions [72]. This
generalized hyperalgesia implicated central sensitization as
an underlying mechanism. Consistent with these findings,
another event-related potentials study showed that painful
CO
2
laser stimulation over the pericranial zone leads to a
higher amplitude of the N2a-P2 complex together with a
higher degree of pericranial muscle tenderness in patients
with chronic TTH than in controls [73].
Neural plasticity in the pathogenesis of MOH has also
been linked to sensitization. Using SSEP, studies have shown
an increase in the amplitude of painful and nonpainful
cortical responses, with the latter normalizing following
recovery from MOH [20, 21, 74]. These abnormalities in
cortical responses to somatosensory stimulation seem to
be strongly influenced by genetic factors and the types of
medications being overused [74, 75]. Sensitization has also
been observed at the level of the spinal cord, where the
activity of the endocannabinoid system was reported to
be enhanced in patients with MOH and normalized after
detoxification [76, 77]. Animals treated with analgesics as a
model of MOH demonstrated increased pain perception, as
manifested in terms of lower withdrawal reflex thresholds
[78]. This change could be gradually reversed after stopping
drug infusion, but a different study showed that sensitization
may persist even after drug discontinuation [79].
3.2. Habituation. Habituation refers to “a response decre-
ment as a result of repeated stimulation” [80], and patients
with migraine often show a “lack of habituation,” that is,
no decrease—or even an increase—in response following
repetitive stimulation. These migraine-related deficits in the
normal habituation phenomenon have been most thor-
oughly examined using the method of visual evoked poten-
tials (VEP), although similar findings have been reported
with a number of other methods, including somatosen-
sory and auditory evoked potentials, blink reflex, and laser
evoked potentials [14]. Interestingly, the defective habitua-
tion appears to normalize immediately before or during a
migraine attack (preictal/ictal periods). In patients with CM,
the habituation pattern during interictal periods is similar to
that during a migraine attack, indicating CM as a status of
never-ending migraine [15, 74, 81–83].
Research also suggests that changes in habituationmay be
associated with the transition from EM to CM. Habituation
studies using nonpainful somatosensory evoked potentials
(SSEP) have reported similarities between the electrophys-
iological patterns of ictal EM and CM, including initial
excessive cortical activation followed by normal habituation
during stimulus repetition [20]. Aurora and colleagues have
shown reduced visual suppression to transcranial magnetic
stimulation (TMS) in patients with EM, which becomes
more severe with CM (Table 1) [18, 19]. Consistent with these
findings, we have used magnetoencephalography (MEG)
to demonstrate that CM patients consistently show pat-
terns of cortical excitability similar to those of ictal EM
[16] and provide evidence of plasticity associated with CM
remission back to interictal EM (Table 1) [17]. The mecha-
nisms underlying interictal deficits in habituation and the
associated changes accompanying migraine chronification
remain largely unknown. In general, both habituation and
sensitizationmay result from repeated stimulation, and it has
therefore been proposed that these two opposing processes
compete to determine the final response [84]. Consistent
with this hypothesis, an imbalance between inhibitory and
excitatory cortical mechanisms—perhaps primary or sec-
ondary to abnormal thalamic control, which is due in turn
to hypoactive aminergic projections from the brainstem—
has been proposed as the culprit in the abnormal habituation
response (for a review see [14]).
A lack of habituation in the blink reflex on the affected
side has been observed in episodic CH patients [65, 85,
86]. The habituation slope was positively correlated with the
number of days since the onset of the CH bout and with the
daily attack frequency [86].
Moreover,MOHpatients have also shown deficient habit-
uationmechanisms during contingent negative variation [87]
and laser-evoked potential [88] recordings and dysfunction
of the inhibitory circuits by TMS [89].
3.3. Defective Endogenous Pain Modulation. The role of the
central nervous system in pain is not limited to the processing
of nociception from the periphery to the higher order regions
of the brain; rather, the central nervous system is capable
of actively modulating pain perception through descending
pain modulatory mechanisms. Among the oldest theories of
central inhibition, spinal gate control theory posits a top-
down mechanism operating from the cortex to modulate
the responses of dorsal horn neurons in the spinal cord
[90]. Diffuse noxious inhibitory control (DNIC), also known
as conditioned pain modulation in humans, is an excellent
example of this type of descending modulation [91]. Origi-
nally characterized in rats, DNIC refers to the phenomenon
by which the application of a tonic painful conditioning
stimulus results in an inhibition of dorsal horn neurons and
associated sensory and motor responses [92]. Dysfunction
of this network (i.e., disinhibition) has been observed in
various pain disorders [93–97], andmay therefore represent a
pathophysiological mechanism underlying pain disorders of
different etiology.
To date, a number of studies have shown vastly altered
endogenous painmodulation inmigraine patients. In the first
exploration of DNIC dysfunction associated with migraine,
researchers used the cold pressor test as a conditioning
stimulus and assessed the nociceptive flexion reflex [98]. As
expected, healthy volunteers experienced significant inhibi-
tion of the nociceptive flexion reflex during the cold pressor
test. On the other hand, patients suffering migraine and
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Table 1: Neural plasticity in episodic and chronic migraine, without medication overuse.
Episodic migraine (EM) Chronic migraine (CM)
Electrophysiology
VEP Lack of habituation and peri-ictal normalization [14] No specific study
MEG
Peri-ictal normalization of visual cortical excitability,
reflecting a dynamic modulation of cortical activities
[15]
Persistent ictal-like visual cortex excitability [16]; in
patients who remitted from CM to EM, the MEG
pattern shifted to that characterizing EM between
attacks, that is, decreased initial amplitude with
subsequent deficient habituation [17]
TMS
Hyperexcitability measured by TMS indices of
phosphene thresholds and magnetic suppression of
perceptual accuracy [18]
Reduced visual suppression correlating with high
cortical excitability [18, 19]
SSEP
Abnormal habituation during interictal period and
central sensitization (increase of N20-P25 amplitude)
during ictal period [14]
Increase of N20-P25 amplitudes recorded interictally in
patients with CM compared with in patients with EM,
indicating excessive cortical activation of the
somatosensory pathway [20]
BAEP Lack of habituation of wave IV-V, especially withsymptomatic vertigo [14] No specific study
LEP
Lack of habituation of N1 (generated by secondary
somatosensory cortex) and N2-P2 (generated by ACC
and insula) during interictal and ictal periods
Sensitization represented by increased N2-P2 amplitude
in the ipsilateral headache side during ictal period [14]
Increase of amplitudes and rostral shift within ACC in





Activation of certain brain areas during ictal period
indicating the involvement of specific brain areas
associated with various symptoms in migraine
including photophobia, nausea, and vertigo [23–26]
Ligand PET: changes of serotonin and opioid receptors
and activities, indicating possible roles these
neurotransmitters play and related neural plasticity
associated with migraine [27, 28]
Increased cerebral metabolism at brainstem compared
to the global flow and also decreased cerebral
metabolism in the medial frontal, parietal, and
somatosensory cortex, indicating a potential
dysfunction in the inhibitory pathways [19]
fMRI Greater activation of pain-matrix areas and lessactivation of pain inhibition areas [29] No specific study
rs-fMRI
Aberrant functional connectivity mostly in pain-matrix
and also involving different networks including
salience, default mode, central-executive, somatomotor,
and frontoparietal attention networks [29]
Aberrant functional connectivity in affective pain
regions including anterior insula, amygdala, pulvinar,
mediodorsal thalamus, middle temporal cortex, and
periaqueductal gray [30]
Structural
VBM Decrease of gay matter volume of multiple brain areaswithin pain-matrix [31–37]
No specific study; only two studies recruited small
numbers of CM patients (11 and 3 patients each)
without definite conclusions [33, 35]
SBM
Increase thickness of the somatosensory cortex and
visual motion areas [38, 39]; no changes [40]; thickness
of somatosensory cortex decrease in low frequency (1-2
days/month) and increase in high frequency (8–14
days/month) [41]; mixed results of increase and




Changes of white matter microstructures in areas such
as corpus callosum and cingulate gyrus [36, 44–50]
Dynamic alteration of fractional anisotropy noted at
thalami, in relation with peri-ictal/ictal status [51]




Episodic migraine (EM) Chronic migraine (CM)
Biochemical
MRS
Higher NAA/Cr ratio at dorsal pons, indicating
possible neuronal hypertrophy; inverse correlation with
headache frequency and intensity [53]
Changes of the excitatory glutamate in the ACC and
insula, indicating [54]
Lower NAA/Cr as compared with EM with inverse
correlation with headache frequency and intensity,
indicating possible progression of neuronal loss during
evolution [53]
VEP: visual evoked potential, MEG: magnetoencephalography, TMS: transcranial magnetic stimulation, SSEP: somatosensory evoked potential, BAEP:
brainstem auditory evoked potential, LEP: laser evoked potential, ACC: anterior cingulate cortex, PET: positron emission topography, fMRI: functional
magnetic resonance imaging, rs-fMRI: resting state functional magnetic resonance imaging; VBM: voxel-based morphometry, SBM: surface-based
morphometry, DTI: diffusion tensor imaging, MRS: magnetic resonance spectroscopy, and NAA/Cr: N-acetylaspartate/creatine.
chronic TTH showed facilitation, rather than inhibition, of
the nociceptive flexion reflex, thereby indicating dysfunction
in the systems underlying DNIC [98]. Similar findings have
been reported in migraine patients, especially those with
medication overuse (MO) [76].
As we sawwith habituation, changes inDNICmay also be
associated with the transformation from EM to CM. Using
capsaicin as a conditioning stimulus, research has shown
increased R2 area of the blink reflex in CM sufferers, as
compared to their EM (with aura) counterparts [99]. The
results suggest that patients with CM experience more severe
dysfunction of the DNIC than those who only experience
occasional attacks. However, it is worth noting that negative
results have also been reported in studies of DNIC changes
associated with migraine, suggesting that the changes may be
quite subtle [100, 101].
4. Neuroimaging Evidence of Neural Plasticity
in Chronic Headaches
4.1. Functional Neuroimaging. Functional neuroimaging has
played a remarkable role in elucidating the pathophysiology
of migraine, from demonstrating that hypoperfusion and
cortical spreading depression are the underlyingmechanisms
of visual aura [102, 103] to suggesting that the brainstem
may be a “migraine generator” [104–106]. The majority of
these studies have been designed to capture the activity of the
brain during migraine attacks, that is, during the ictal period.
Nonetheless, a number of studies have investigated patients’
brain responses to painful and other stimuli during interictal
periods.They have consistently observed increased activation
of a network of brain regions collectively known as the “pain-
matrix” (i.e., a term, now progressively running out of favor,
traditionally used to describe a collection of regions acti-
vated by painful stimulation, and including the primary and
secondary somatosensory cortices, anterior cingulate cortex,
insula, prefrontal cortex, the thalamus and others [107]).
Decreased activation can be vice versa observed in areas
responsible for pain inhibition (e.g., pons, ventral medulla),
thereby suggesting an imbalance between facilitation and
inhibition likely resulting from maladaptive neural plasticity
(for review, see [29]).
Significant efforts have also been made to link migraine
to abnormalities in functional connectivity measured by
resting-state fMRI (rs-fMRI). Unlike experiments examining
brain responses to stimuli (including both experimentally
applied stimulation and clinical pain), functional connectiv-
ity experiments instead look for concurrent fluctuations of
the fMRI signals during a task-free rest period [108].This line
of research has revealed patterns of aberrant functional con-
nectivity in patientswithmigraine andhas also noted an asso-
ciation between degree of connectivity and clinical variables,
such as headache frequency and disease duration [29]. For
instance, a rs-fMRI study has revealed that with increasing
frequency of monthly migraine attacks the periaqueductal
gray, a key node in the descending pain modulatory system
[109–111], becomes more functionally connected to pain
processing regions (e.g., insula and secondary somatosensory
cortex) and less functionally connected to pain-modulatory
regions (e.g., orbitofrontal cortex) [112]. Similar to the results
from stimulus- or task-related fMRI, these resting state stud-
ies also suggest that dysfunctional dynamics between pain
modulatory and pronociceptive regions may be implicated in
the pathophysiology of migraine.
While some of the abovementioned experiments have
been conducted exclusively with CM patients, many of the
studies in the literature have been limited by their inclusion
of both chronic and episodicmigraine patients. Among those
that have focused on CM, a combined electrophysiology
and PET study noted increased cerebral metabolism in the
brainstem [19]. A rs-fMRI study showed that functional
connectivity with affective pain regions differed between CM
patients and controls in a number of regions, including the
anterior insula, amygdala, pulvinar, mediodorsal thalamus,
middle temporal cortex, and periaqueductal gray [30]. It was
further found that connectivity in some of these regions
correlated with disease duration.
Just like migraine, recent years have seen many neu-
roimaging studies probing the etiology of episodic and
chronic CH. Early PET studies provided evidence of activa-
tion in the ipsilateral hypothalamus, contralateral thalamus,
anterior cingulate cortex, and bilateral insulae in CH [113,
114], with activation of the hypothalamus appearing to be
specifically associatedwith pain attacks [115]. Similar patterns
of neural response have been confirmed across imaging
modalities, with fMRI studies reporting activation of the
hypothalamus, prefrontal cortex, anterior cingulate cortex,
contralateral thalamus, ipsilateral basal ganglia, insula, and
bilateral cerebellum during bouts of CH [116]. Finally,
functional imaging has also demonstrated alterations in
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functional connectivity, including at the level of the primary
visual network and between hypothalamus and its connec-
tions with frontal, occipital, and cerebellar areas in CH
patients [117–119].
Neuroimaging studies have provided valuable informa-
tion on neural plasticity underlying MOH as well. An
early PET study provided evidence of hypometabolism in
the orbitofrontal cortex that persisted after detoxification,
implying that the dysfunction observed is the cause, rather
than a consequence, of MOH [120]. An fMRI study reported
hypoactivation of the right supramarginal gyrus and the
right inferior and superior parietal cortex, all of which
recovered near normal patterns of activation six months after
medication withdrawal [121]. These areas may be involved in
painmodulation. Another fMRI study showed dysfunction in
the mesocorticolimbic dopamine circuit, including the ven-
tromedial prefrontal cortex and the substantia nigra/ventral
tegmental area complex [122]. Dysfunction in the ventrome-
dial prefrontal cortex was reversible following withdrawal,
while dysfunction in the substantia nigra/ventral tegmental
area complex remained persistent. The results suggest that
the mechanisms of MOH may involve the dopaminergic
reward system, similar to other chronic pain disorders such
as fibromyalgia [97, 123].
4.2. Structural Neuroimaging
4.2.1. Gray Matter: Voxel- and Surface-Based Morphometry
Studies. Studies from a wide variety of chronic pain condi-
tions, including chronic back pain [124], fibromyalgia [125–
128], rheumatoid arthritis [129], menstrual pain [130], and
vulvar pain [131], indicate that long term exposure to pain
might cause structural alterations in a number of brain
regions [132]. The most common approach to assessing gray
matter structure is that of voxel-based morphometry (VBM).
Except for the very first publication to apply the method to
headache (which reported no change), VBM studies have
consistently found decreases in gray matter volume in mul-
tiple brain areas that broadly overlap with the “pain-matrix”
[31–37]. Several studies have further provided evidence that
within migraine sufferers, gray matter volume may change
dynamically between ictal and interictal periods [133] and
that gray matter volume changes more broadly correlate
with attack frequency [34–36]. As with functional imaging,
these findings are limited by the studies’ focus on episodic
migraine. Only two of the studies described here recruited
any CM patients without history of MO, with relatively small
sample sizes (11 and 3 patients each) [33, 35].
The mechanisms underlying structural changes in the
brain associated with migraine remain to be determined.
Based simply on the similarity of findings between migraine
studies and those of other headache subtypes and other
pain disorders, it has been proposed that these changes
are consequences rather than causes of repeated attacks
[134]. One potential mechanism underlying the effect of
continuous exposure to pain on structural integrity may
be neuroinflammation. Using integrated positron emission
tomography/magnetic resonance imaging (PET/MRI), Log-
gia et al. have observed evidence of neuroinflammation/glial
activation in the brain of chronic low back pain, most promi-
nently in the thalamus [135]. As the thalamus was shown
to exhibit reduced gray matter volume in the same patient
population [124], it is possible that the excessive production
of cytokines and other proinflammatory chemicals released
by activated glia [136] represents pathophysiological mecha-
nisms responsible for the structural alterations observed in
chronic pain conditions. However, future studies will need to
investigate whether glial activation is observed in other pain
disorders, including migraine.
Another technique used to evaluate structural alteration
in patients with migraine and other pain disorders is surface-
based morphometry, a technique that allows the measure-
ment of cortical thickness instead of volume [137]. It is
worth noting that, while cortical thinning and reductions in
gray matter density/volume are more commonly reported in
chronic pain disorders, increases in structural metrics have
also been described, such as in fibromyalgia and in chronic
vulvar pain [127, 131].
In line with these observations, two early studies by
Hadjikhani and colleagues reported increased, rather than
decreased, cortical thickness in the somatosensory and
visual motion areas in patients with EM [38, 39]. A subse-
quent study by Maleki et al. examined potential differences
between patients with low (1-2 days/month) and high (8–14
days/month) headache frequencies [41]. The group reported
reduced cortical thickness in the low frequency group and
increased cortical thickness in the high frequency group.
Other researchers have found mixed results, reporting both
increases and decreases in cortical thickness in different brain
regions, as well as different directions in the association
between cortical thickness and clinical parameters, such as
disease duration and attack frequency [42, 43]. It is also
worth noting that, while changes in cortical thickness are
a normal part of ageing, the correlations between cortical
thickness, cutaneous pain threshold, and age are atypical in
episodic migraine patients [138, 139]. Again, the biological
mechanisms underlying these structural changes and their
relation with clinical and psychophysical parameters need to
be elucidated and may reflect the differential contributions
of various neuroinflammatory processes, such as swelling,
gliosis, excitotoxicity-mediated necrosis, and others.
Structural imaging studies of CH also have had mixed
results, disagreeing not only on the brain regions affected, but
even on the direction of grey matter volume changes. Using
VBM, a pioneering structural imaging study revealed gray
matter volume increases in the bilateral posterior hypotha-
lamus, a region colocalized with the functional changes
observed in PET imaging of CH [140]. Examining episodic
CH patients during pain-free “out-bout” periods, other
studies have suggested gray matter volume decreases in areas
associated with the pain-matrix, including the thalamus,
anterior cingulate cortex, insula, basal ganglia, cingulum, and
frontal cortex [141, 142]. Others still have shown evidence
of dynamic alterations in gray matter volume in regions
such as the temporal lobe, hippocampus, insular cortex,
and cerebellum [143]. These regions have been implicated
in a number of pain related functions, including attention
and emotion regulation, fear conditioning, and nociceptive
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encoding during pain perception and processing. Further-
more, in patients with chronic CH, gray matter decreases
were noted in multiple areas involved in pain modulation
[143]. The same study reported negative correlations of gray
matter volumewith disease duration andpositive correlations
with attack interval, indicating that gray matter undergoes
dynamic and reversible changes during the various stages of
CH.
Reversibility of morphological changes has been reported
in other chronic pain conditions, including a recent surface-
based morphometry study [144] demonstrating that success-
ful treatment in patients with chronic back pain may reverse
not only abnormal brain function, but also abnormal brain
structure: after treatment, patients had increased cortical
thickness in the left dorsolateral prefrontal cortex, which
was thinner before treatment compared to controls. This
observation again suggests that brain plasticity in response
to pain is bidirectional.
Decreases in gray matter volume of pain-related brain
structures were also reported in patients with chronic TTH,
including anterior cingulate cortex, insula, orbitofrontal cor-
tex, parahippocampal gyrus, and dorsal rostral pons [145].
These decreases were positively correlated with headache
duration, which, as the authors suggest, may be an indica-
tion of structural changes being the consequence of central
sensitization.
In MOH patients with migraine history, significant gray
matter volume decreases were reported in the orbitofrontal
cortex, anterior cingulate cortex, insula and precuneus, as
well as volume increases in the periaqueductal gray, thalamus
and ventral striatum [115]. The same group later published
posttreatment results, reporting that the gray matter volume
increases in the midbrain returned to baseline only in the
subset of patients experiencing clinical improvement. Low
gray matter volume in the orbitofrontal cortex was also
associatedwith poor treatment response [146]. A recent study
explored both functional connectivity and morphological
changes in MOH patients with migraine, using EM patients
and healthy volunteers as controls [147].The authors reported
no structural differences in group comparisons but did
identify negative correlations betweenmigraine duration and
gray matter volume in the frontal regions, precuneus, and
hippocampus.
4.2.2.WhiteMatter. While the clinical significance is unclear,
migraine patients have well-documented whitematter hyper-
intensities [148]. To explore these white matter changes,
most studies have adopted the method of diffusion tensor
imaging (DTI). DTI allows for visualization of the orientation
and anisotropy of water diffusion, which in turn allows for
detection of microstructural alterations of white matter not
visible by conventional MRI [53]. Studies using different
methods (e.g., histogram-based analysis, region-of-interest,
or tract-based spatial statistics), exploring both whole brain
and targeted brain areas, have reported changes in various
DTI parameters [36, 44–50]. As with gray matter stud-
ies, it remains unknown whether these changes contribute
to headache chronification or are merely consequences of
headache. Dynamic alterations in thalamic microstructure
(higher fractional anisotropy in the interictal phase, which
normalized during the ictal phase) have been reported,
perhaps reflecting plastic peri-ictal modifications of local
fibers [51]. To date, only one study has recruited patients
with CM, but the results showed no changes in any DTI
parameters in patients with CM or EM, as compared to
healthy controls [52]. However, 15 (71%) of the 21 CMpatients
reported concomitant MO, potentially confounding results.
In addition to migraine, DTI studies have provided evidence
of changes in patients with CH regarding white matter
diffusivity throughout the brain, including the pain-matrix
[141, 149–151].
4.3. Biochemical Neuroimaging. Another promising line of
research in the study of the neural mechanisms underlying
chronic headache or pain disorders is represented by the
use of magnetic resonance spectroscopy (MRS). MRS allows
noninvasive and in vivo exploration of the molecular compo-
sition of tissue, by identifying certain metabolites involved in
physiological or pathological processes. By using techniques
such as single voxel spectroscopy or chemical shift imaging,
researchers were able to reveal the presence of biochemical
alterations in the brain of patients with various chronic pain
disorders. For instance, studies have demonstrated a reduced
concentration of N-Acetylaspartate (NAA), a marker of neu-
ronal integrity in chronic low back pain [152–156], complex
regional pain syndrome [157], fibromyalgia [158–160], and
neuropathic pain patients [161–163], in various brain regions.
Other studies have revealed increases in the concentration
of the excitatory neurotransmitter glutamate (Glu), or of a
combination of glutamate/glutamine in fibromyalgia [158,
164, 165], but decreases in chronic low back pain patients
[156].
Despite the great potential, not many MRS studies have
been conducted in migraine patients. Of those that have
been conducted, the majority focus on disturbed energy
metabolism, indicating a possible role of mitochondrial dys-
function in migraine pathophysiology [166]. Another study
has revealed decreases in NAA and glutamate and increases
in the concentration of myoinositol, in the cerebellar vermis
of patients with familial hemiplegic migraine type 1 [167].
Our group has compared 1H-MRS metabolite ratios in EM
and CM patients [168]. Patients with EM presented with
the elevated NAA/creatine (Cr) ratios at the dorsal pons,
indicating possible neuronal hypertrophy. On the contrary,
CM patients had NAA/Cr levels similar to those of healthy
controls. The NAA/Cr ratios were inversely correlated with
headache frequency and intensity. We propose that the
repetitive noxious stimuli might pose a detrimental effect
leading to the neuronal loss of this region during migraine
evolution from EM to CM.
5. Genetic Aspects of Neural Plasticity in
Chronic Headaches
Genes may influence the cerebral processes that lead to the
progression from episodic to chronic headache and deter-
mine distinctive morphofunctional properties [169]. Most
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studies in the genetic aspect of neural plasticity associated
with chronic headaches focused on migraine and MOH.
Though few in number, studies have been conducted to
examinewhether select gene polymorphismsmight influence
neural plasticity (habituation/sensitization) in MOH. The
angiotensin-converting enzyme D/D genotype appears to
serve as an influencing factor in migraine attack frequency
[170], as well as in substance abuse behavior [171, 172]. Di
Lorenzo et al. [75] found that D/D carriers presented with
the highest grand averaged SSEP amplitudes, reflecting sensi-
tization, and the most severe deficits in habituation, although
other MOH patients overall did not habituate either. This
abnormal electrophysiological pattern gradually disappeared
in the D/I and I/I carriers, in whom the cortical response
habituated normally. Moreover, the group has observed that
angiotensin-converting enzyme polymorphisms influence
overuse behavior: in patients carrying the D/D genotype,
more prolongedMOH is associated with greater sensitization
and greater habituation deficits [75].
Considering that MOH bears resemblance to an abuse
disorder and that previously identified susceptibility genes,
such as the angiotensin-converting enzyme polymorphism,
have also been linked to substance abuse behavior, researchers
have sought to examine whether there are psychiatric differ-
ences between MOH sufferers with various polymorphisms.
Researchers have examined whether the brain-derived neu-
rotrophic factor (BDNF) Val66Met and wolframinHis611Arg
(WFSI) polymorphisms, both being linked to psychiatric ill-
ness and dependence behavior,might be related also toMOH.
They observed that individuals carrying the RR WFSI [173]
and the non-G/GBDNF [174] genotypes showed significantly
higher monthly drug consumption than non-R/R WFSI and
G/G BDNF carriers. On the same notion, Terrazzino et al.
[175] found that MOH patients carrying the 516T serotonin
5HT2A receptor gene polymorphism, but not that of A-
1438G, have significantly higher monthly drug consumption
than their 516CC counterparts.
Others have taken an epigenetic approach with the hopes
of assessing whether gene expression patterns may change
along with patients’ migraine state. Hershey et al. [176, 177]
found unique gene expression patterns in the subset of
MOH patients who responded to analgesic detoxification.
Gene ontology indicated that many of the identified genes
are involved in cell signaling pathways, phosphorylation of
cellular components, and immunological pathways [177].
Genetic linkage studies have reported a significant associ-
ation between CM and the long allele of monoamine oxidase
A 30 bp VNTR and CYP1A2∗1F variant, both enzymes
responsible for triptan degradation [178]. The latter variant
was found to be significantly associated with triptan overuse
and drug response within MOH patients [179]. Knowing
the important role of dopamine brain circuitry in drug
dependence behavior, researchers have assessed the role
of dopamine metabolism-related genes on susceptibility to
MOH [180]. Allele 10 of the dopamine transporter gene
was significantly underrepresented in patients with MOH
when compared with episodic migraine sufferers. However,
a recently published candidate-gene association study failed
to find any significant associations between high-frequency-
to-chronic migraine and the 144 single-nucleotide poly-
morphisms previously implicated in migraine or identified
as interesting secondary hits in genome-wide association
studies [181].
In summary, inheritance appears to play an important
role in determining predisposition to specific clinical man-
ifestations of migraine and the progression to CM, especially
when related toMOH. Furthermore, the association between
gene polymorphisms and characteristic neurophysiologic
patterns in CM suggests that genetics can influence the
way the brain responds plastically to chronic head pain and
excessive drug consumption.
6. The Link between Neural Plasticity and
Headache Chronification
To date electrophysiological and neuroimaging studies have
revealed different aspects of neural plasticity associated with
chronic headaches, especially migraine. Table 1 compares
these study findings between EM and CM to characterize
the neural plasticity associated with migraine chronification.
Of note, migraine chronification involves various aspects of
neural plasticity in pain-related neural networks. Despite
inconclusive findings in brain structures, earlier studies
have characterized neural plasticity in association with CM
evolution by brain excitability change (central sensitization,
habituation change, impaired inhibition), altered biochem-
istry and metabolism, and aberrant functional connectivity.
Some studies (please refer to MEG and LEP in Table 1)
further suggest an ictal-like response pattern in interictal
periods of CM. Taken together, it is assumed that chronic
headache may be an abnormal functional status of never-
ending headache underpinned by neural plastic responses
to recurrent headaches. Genetic predisposition, as discussed
above, may influence the evolution of chronic headaches.
However, the true genetic effect upon neural plasticity can
only be disentangled if the complex interaction between
genes and electrophysiology or neuroimaging can be clarified
in future longitudinal studies.
Other common forms of chronic headaches, such as
chronic CH and chronic TTH and MOH, also share some
features of neural plasticitywithCM,notably changes in brain
excitability (Table 1). Nevertheless, it remains undetermined
whether these common features of neural plasticity can be
regarded as neurologic signatures for chronic headaches.
It is unknown either whether there are headache-specific
neural plasticity that may help differentiate between chronic
headaches or develop mechanism-based therapy against
chronic headaches.
7. Conclusion
Neural responses to episodic headache are initially adaptive
and physiologic but later become maladaptive and patho-
logic, eventually creating a vicious cycle resulting in chronic
headache. This process of headache evolution is associated
with neural plasticity in brain excitability, biochemistry,
function, and even structures. Genetic factors are likely to
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contribute to this process. Further studies are needed to eluci-
date if there are common features of neural plasticity among
various chronic headaches that may serve as neurologic
signatures for chronic headaches, or conversely, headache-
specific neural plasticity that may help in the diagnosis and
treatment of different chronic headaches.
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